Glenmark Pharmaceuticals Limited (BOM:532296)
2,274.25
-108.40 (-4.55%)
At close: May 29, 2026
Glenmark Pharmaceuticals Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Cash & Equivalents | 11,763 | 16,757 | 16,583 | 11,592 | 14,105 |
Short-Term Investments | - | 63.45 | 57.81 | 90.67 | 57.33 |
Cash & Short-Term Investments | 11,763 | 16,821 | 16,641 | 11,683 | 14,163 |
Cash Growth | -30.07% | 1.08% | 42.44% | -17.51% | 23.43% |
Accounts Receivable | 49,634 | 33,419 | 18,584 | 36,652 | 31,011 |
Other Receivables | - | 5,710 | 8,225 | 5,743 | 5,576 |
Receivables | 49,634 | 39,130 | 26,809 | 42,394 | 36,588 |
Inventory | 34,308 | 30,285 | 25,131 | 23,736 | 24,998 |
Prepaid Expenses | - | 1,053 | 266.9 | 2,275 | 2,199 |
Other Current Assets | 17,293 | 5,667 | 5,434 | 27,167 | 4,876 |
Total Current Assets | 112,997 | 92,955 | 74,281 | 107,255 | 82,823 |
Property, Plant & Equipment | 43,174 | 38,614 | 35,375 | 41,951 | 46,117 |
Long-Term Investments | 423.56 | 605 | 7,958 | 472.77 | 556.64 |
Goodwill | 828.64 | 702.66 | 673.59 | 736.19 | 600.19 |
Other Intangible Assets | 24,234 | 13,900 | 12,672 | 23,427 | 22,254 |
Long-Term Deferred Tax Assets | 12,466 | 11,241 | 10,497 | 18,059 | 16,861 |
Other Long-Term Assets | 4,955 | 2,478 | 2,130 | 1,816 | 1,620 |
Total Assets | 199,079 | 160,496 | 143,586 | 193,717 | 170,833 |
Accounts Payable | 37,439 | 25,795 | 25,359 | 20,004 | 22,887 |
Accrued Expenses | - | 11,132 | 12,473 | 14,427 | 7,168 |
Short-Term Debt | - | 16,815 | 8,334 | 3,500 | 3,700 |
Current Portion of Long-Term Debt | - | - | 1,572 | 1,456 | 7,286 |
Current Portion of Leases | 1,072 | 922.62 | 886.43 | 830.39 | 916.78 |
Current Income Taxes Payable | 945.29 | 283.74 | 2,910 | 984.98 | 931.2 |
Other Current Liabilities | 24,308 | 4,722 | 6,652 | 9,848 | 4,005 |
Total Current Liabilities | 63,764 | 59,670 | 58,186 | 51,051 | 46,894 |
Long-Term Debt | - | 5,127 | - | 38,521 | 25,717 |
Long-Term Leases | 4,863 | 1,862 | 1,517 | 1,771 | 2,000 |
Long-Term Deferred Tax Liabilities | 12.31 | 585.88 | 2.8 | 5.14 | 314.95 |
Other Long-Term Liabilities | 25,321 | 4,760 | 5,405 | 3,976 | 1,525 |
Total Liabilities | 93,961 | 72,005 | 65,111 | 95,324 | 76,452 |
Common Stock | 282.2 | 282.19 | 282.19 | 282.17 | 282.17 |
Additional Paid-In Capital | - | 16,866 | 16,866 | 16,854 | 16,854 |
Retained Earnings | - | 89,140 | 80,160 | 96,026 | 93,564 |
Comprehensive Income & Other | 104,839 | -17,793 | -18,828 | -18,422 | -19,834 |
Total Common Equity | 105,121 | 88,494 | 78,479 | 94,739 | 90,866 |
Minority Interest | -3.16 | -3.71 | -3.8 | 3,653 | 3,515 |
Shareholders' Equity | 105,118 | 88,491 | 78,475 | 98,393 | 94,381 |
Total Liabilities & Equity | 199,079 | 160,496 | 143,586 | 193,717 | 170,833 |
Total Debt | 5,935 | 24,727 | 12,309 | 46,079 | 39,620 |
Net Cash (Debt) | 5,827 | -7,906 | 4,331 | -34,396 | -25,458 |
Net Cash Per Share | 20.64 | -28.02 | 15.35 | -121.90 | -90.22 |
Filing Date Shares Outstanding | 282.22 | 282.19 | 282.19 | 282.17 | 282.17 |
Total Common Shares Outstanding | 282.22 | 282.19 | 282.19 | 282.17 | 282.17 |
Working Capital | 49,233 | 33,284 | 16,095 | 56,205 | 35,929 |
Book Value Per Share | 372.48 | 313.60 | 278.11 | 335.75 | 322.03 |
Tangible Book Value | 80,059 | 73,891 | 65,134 | 70,576 | 68,012 |
Tangible Book Value Per Share | 283.67 | 261.85 | 230.82 | 250.12 | 241.04 |
Land | - | 471.82 | 461.25 | 423.45 | 688.97 |
Buildings | - | 18,588 | 17,556 | 16,069 | 17,211 |
Machinery | - | 35,618 | 32,155 | 32,052 | 34,167 |
Construction In Progress | - | 5,420 | 4,193 | 10,658 | 9,211 |